216 related articles for article (PubMed ID: 37940929)
21. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
Mitsuhashi A; Sato Y; Kiyokawa T; Koshizaka M; Hanaoka H; Shozu M
Ann Oncol; 2016 Feb; 27(2):262-6. PubMed ID: 26578736
[TBL] [Abstract][Full Text] [Related]
22. Identification of novel serum biomarker for the detection of acute myeloid leukemia based on liquid chromatography-mass spectrometry.
Wang D; Tan G; Wang H; Chen P; Hao J; Wang Y
J Pharm Biomed Anal; 2019 Mar; 166():357-363. PubMed ID: 30690249
[TBL] [Abstract][Full Text] [Related]
23. Serum lipidomic profiling by UHPLC-MS/MS may be able to detect early-stage endometrial cancer.
Cheng F; Fan W; Gui L; Liu Y; Ling Y; Huang R; Wen Z; Chen Y
Anal Bioanal Chem; 2023 Apr; 415(10):1841-1854. PubMed ID: 36799979
[TBL] [Abstract][Full Text] [Related]
24. Metabolic syndrome is an independent risk factor for time to complete remission of fertility-sparing treatment in atypical endometrial hyperplasia and early endometrial carcinoma patients.
Ding Y; Fan Y; Li X; Wang Y; Wang J; Tian L
Reprod Biol Endocrinol; 2022 Sep; 20(1):134. PubMed ID: 36064542
[TBL] [Abstract][Full Text] [Related]
25. Discovery of potential biomarkers in acute kidney injury by ultra-high-performance liquid chromatography-tandem quadrupole time-of-flight mass spectrometry (UPLC-Q/TOF-MS).
Chen C; Zhang P; Bao G; Fang Y; Chen W
Int Urol Nephrol; 2021 Dec; 53(12):2635-2643. PubMed ID: 33686532
[TBL] [Abstract][Full Text] [Related]
26. Accurate quantification of urinary metabolites for predictive models manifest clinicopathology of renal cell carcinoma.
Sato T; Kawasaki Y; Maekawa M; Takasaki S; Shimada S; Morozumi K; Sato M; Kawamorita N; Yamashita S; Mitsuzuka K; Mano N; Ito A
Cancer Sci; 2020 Jul; 111(7):2570-2578. PubMed ID: 32350988
[TBL] [Abstract][Full Text] [Related]
27. Urinary and Plasma Metabolomics Identify the Distinct Metabolic Profile of Disease State in Chronic Mouse Model of Multiple Sclerosis.
Singh J; Cerghet M; Poisson LM; Datta I; Labuzek K; Suhail H; Rattan R; Giri S
J Neuroimmune Pharmacol; 2019 Jun; 14(2):241-250. PubMed ID: 30315511
[TBL] [Abstract][Full Text] [Related]
28. Metabolic analysis of early nonalcoholic fatty liver disease in humans using liquid chromatography-mass spectrometry.
Hu C; Wang T; Zhuang X; Sun Q; Wang X; Lin H; Feng M; Zhang J; Cao Q; Jiang Y
J Transl Med; 2021 Apr; 19(1):152. PubMed ID: 33858428
[TBL] [Abstract][Full Text] [Related]
29. Significance of serum and pathological biomarkers in fertility-sparing treatment for endometrial cancer or atypical hyperplasia: a retrospective cohort study.
Wang Y; Zhou R; Zhang X; Liu H; Shen D; Wang J
BMC Womens Health; 2021 Jun; 21(1):252. PubMed ID: 34162378
[TBL] [Abstract][Full Text] [Related]
30. LC-MS metabolomics of urine reveals distinct profiles for non-muscle-invasive and muscle-invasive bladder cancer.
Oto J; Fernández-Pardo Á; Roca M; Plana E; Cana F; Herranz R; Pérez-Ardavín J; Vera-Donoso CD; Martínez-Sarmiento M; Medina P
World J Urol; 2022 Oct; 40(10):2387-2398. PubMed ID: 36057894
[TBL] [Abstract][Full Text] [Related]
31. Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia.
Fan Y; Li X; Wang J; Wang Y; Tian L; Wang J
Reprod Biol Endocrinol; 2021 Aug; 19(1):118. PubMed ID: 34344384
[TBL] [Abstract][Full Text] [Related]
32. Targeting amine- and phenol-containing metabolites in urine by dansylation isotope labeling and liquid chromatography mass spectrometry for evaluation of bladder cancer biomarkers.
Chen YT; Huang HC; Hsieh YJ; Fu SH; Li L; Chen CL; Chu LJ; Yu JS
J Food Drug Anal; 2019 Apr; 27(2):460-474. PubMed ID: 30987717
[TBL] [Abstract][Full Text] [Related]
33. LC-MS/MS platform-based serum untargeted screening reveals the diagnostic biomarker panel and molecular mechanism of breast cancer.
Gong S; Wang Q; Huang J; Huang R; Chen S; Cheng X; Liu L; Dai X; Zhong Y; Fan C; Liao Z
Methods; 2024 Feb; 222():100-111. PubMed ID: 38228196
[TBL] [Abstract][Full Text] [Related]
34. [Metabolomics study of urine with Benzene, Toluene and Xylene combined exposure based on ultra performance liquid chromatography-quadrupole time-of-flight mass spectrometry].
Liu XD; Qiao H; Wang C; Meng XJ; Pan XF; Niu DS; Li J
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Apr; 39(4):248-252. PubMed ID: 33910281
[No Abstract] [Full Text] [Related]
35. [Urine metabolomics analysis based on ultra performance liquid chromatography-high resolution mass spectrometry combined with osmolality calibration sample concentration variability].
He Z; Lin H; Gui J; Zhu W; He J; Wang H; Feng L
Se Pu; 2021 Apr; 39(4):391-398. PubMed ID: 34227759
[TBL] [Abstract][Full Text] [Related]
36. [Significance of molecular classification in fertility-sparing treatment of endometrial carcinoma and atypical endometrial hyperplasia].
Wang YQ; Kang N; Li LW; Wang ZQ; Zhou R; Shen DH; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2022 Sep; 57(9):692-700. PubMed ID: 36177581
[No Abstract] [Full Text] [Related]
37. Non-invasive urinary metabolomics reveals metabolic profiling of polycystic ovary syndrome and its subtypes.
Zhou W; Hong Y; Yin A; Liu S; Chen M; Lv X; Nie X; Tan N; Zhang Z
J Pharm Biomed Anal; 2020 Jun; 185():113262. PubMed ID: 32222648
[TBL] [Abstract][Full Text] [Related]
38. High-throughput metabolomic method based on liquid chromatography: high resolution mass spectrometry with chemometrics for metabolic biomarkers and pathway analysis to reveal the protective effects of baicalin on thyroid cancer.
Du HW; Cong W; Wang B; Zhao XL; Meng XC
Anal Methods; 2020 Sep; 12(33):4139-4149. PubMed ID: 32776035
[TBL] [Abstract][Full Text] [Related]
39. Integrated biomarker for type 2 diabetes mellitus and impaired fasting glucose based on metabolomics analysis using ultra-high performance liquid chromatography quadrupole-Orbitrap high-resolution accurate mass spectrometry.
Long J; Liu L; Jia Q; Yang Z; Sun Z; Yan C; Yan D
Rapid Commun Mass Spectrom; 2020 Jun; 34(12):e8779. PubMed ID: 32159245
[TBL] [Abstract][Full Text] [Related]
40. Serum untargeted metabolomics reveal metabolic alteration of non-small cell lung cancer and refine disease detection.
Li J; Liu K; Ji Z; Wang Y; Yin T; Long T; Shen Y; Cheng L
Cancer Sci; 2023 Feb; 114(2):680-689. PubMed ID: 36310111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
